Respondr TNF is a proprietary test that uses objective evidence to predict an individual patient's likelihood of response to infliximab, adalimumab or their biosimilars prior to initiation of therapy.
Saliva-based diagnostic detects genes related to the disease and calculates risk. Prometheus has selected DNA Genotek’s Oragene®•DNA product as the sample-collection kit for MyCeliacID™, a ...
The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...
SAN DIEGO, CA / ACCESS Newswire / April 1, 2025 / Prometheus Laboratories Inc. ("Prometheus"), a leader in precision-guided medicine, announces a new Anser ® therapeutic drug monitoring (TDM) test for ...
SAN DIEGO, July 31, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today the market launch of its proprietary new generation monitoring ...
WASHINGTON (AP) -- The Supreme Court unanimously tossed out medical patent claims for Prometheus Laboratories on Tuesday for a test that could help doctors set drug doses for autoimmune diseases like ...
Many pharmacies across the nation are sold out of Covid-19 rapid diagnostic tests, making it exceedingly difficult for Americans to contain the spread of the Omicron variant of SARS-CoV-2, the virus ...
The German Aerospace Center (DLR) and the European Space Agency (ESA) have signed a further contract as part of the Prometheus project. The DLR Institute of Space Propulsion at the Lampoldshausen site ...
Prometheus Laboratories announced the launch of its monitoring test, PROMETHEUS Anser IFX, which measures infliximab (Remicade; Janssen Biotech) and infliximab antibody levels in one sample to be used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback